1. Home
  2. IMMP vs GRAF Comparison

IMMP vs GRAF Comparison

Compare IMMP & GRAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMMP
  • GRAF
  • Stock Information
  • Founded
  • IMMP 1987
  • GRAF 2021
  • Country
  • IMMP Australia
  • GRAF United States
  • Employees
  • IMMP N/A
  • GRAF N/A
  • Industry
  • IMMP Biotechnology: Pharmaceutical Preparations
  • GRAF
  • Sector
  • IMMP Health Care
  • GRAF
  • Exchange
  • IMMP Nasdaq
  • GRAF NYSE
  • Market Cap
  • IMMP 304.0M
  • GRAF 290.7M
  • IPO Year
  • IMMP N/A
  • GRAF 2024
  • Fundamental
  • Price
  • IMMP $1.93
  • GRAF $10.11
  • Analyst Decision
  • IMMP Buy
  • GRAF
  • Analyst Count
  • IMMP 2
  • GRAF 0
  • Target Price
  • IMMP $8.50
  • GRAF N/A
  • AVG Volume (30 Days)
  • IMMP 98.7K
  • GRAF 18.5K
  • Earning Date
  • IMMP 02-27-2025
  • GRAF 01-01-0001
  • Dividend Yield
  • IMMP N/A
  • GRAF N/A
  • EPS Growth
  • IMMP N/A
  • GRAF N/A
  • EPS
  • IMMP N/A
  • GRAF 0.25
  • Revenue
  • IMMP $2,563,302.00
  • GRAF N/A
  • Revenue This Year
  • IMMP N/A
  • GRAF N/A
  • Revenue Next Year
  • IMMP $47.79
  • GRAF N/A
  • P/E Ratio
  • IMMP N/A
  • GRAF $40.76
  • Revenue Growth
  • IMMP 9.59
  • GRAF N/A
  • 52 Week Low
  • IMMP $1.66
  • GRAF $9.03
  • 52 Week High
  • IMMP $3.34
  • GRAF $11.02
  • Technical
  • Relative Strength Index (RSI)
  • IMMP 42.28
  • GRAF N/A
  • Support Level
  • IMMP $2.00
  • GRAF N/A
  • Resistance Level
  • IMMP $2.05
  • GRAF N/A
  • Average True Range (ATR)
  • IMMP 0.09
  • GRAF 0.00
  • MACD
  • IMMP -0.02
  • GRAF 0.00
  • Stochastic Oscillator
  • IMMP 8.33
  • GRAF 0.00

About IMMP Immutep Limited

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.

About GRAF GRAF GLOBAL CORP

Graf Global Corp is a blank check company.

Share on Social Networks: